Tracks sepsis bundle compliance with lactate timing, fluid resuscitation, and antibiotic administration. Use when managing sepsis protocols, tracking bundle elements, or documenting sepsis care.
Tracks Sepsis-3 identification, SEP-1 bundle compliance, and documents lactate clearance, antibiotic timing, fluid resuscitation, and vasopressor initiation per Surviving Sepsis Campaign guidelines.
Sepsis kills 270,000 Americans annually and is the leading cause of death in US hospitals. CMS SEP-1 is a publicly reported quality measure that tracks six-hour bundle compliance—hospitals with low compliance face financial penalties, reputational damage, and increased mortality. Each hour of delay in appropriate antibiotic administration increases sepsis mortality by 7.6%. Despite this, national SEP-1 compliance hovers around 50%, primarily due to documentation failures rather than clinical care gaps.
The 2021 Surviving Sepsis Campaign guidelines and Sepsis-3 definitions shifted the diagnostic framework from SIRS criteria to qSOFA and SOFA scoring. Understanding these definitions is essential because documentation that conflates SIRS-based sepsis with Sepsis-3 organ dysfunction criteria creates coding and compliance errors.
Sepsis = Suspected or documented infection + acute organ dysfunction (SOFA score increase ≥2 points from baseline)
| Criterion | Threshold | Points |
|---|---|---|
| Altered mental status | GCS <15 | 1 |
| Respiratory rate | ≥22 breaths/min | 1 |
| Systolic blood pressure | ≤100 mmHg | 1 |
qSOFA ≥2 suggests possible sepsis and should trigger further workup. Note: qSOFA is a screening tool, not a diagnostic criterion—it has high specificity but low sensitivity.
| System | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
| Respiration (PaO2/FiO2) | ≥400 | <400 | <300 | <200 with support | <100 with support |
| Coagulation (Platelets x10³) | ≥150 | <150 | <100 | <50 | <20 |
| Liver (Bilirubin mg/dL) | <1.2 | 1.2-1.9 | 2.0-5.9 | 6.0-11.9 | >12 |
| Cardiovascular (MAP/vasopressors) | MAP ≥70 | MAP <70 | Dopa ≤5 or dobutamine | Dopa >5 or epi ≤0.1 or norepi ≤0.1 | Dopa >15 or epi >0.1 or norepi >0.1 |
| CNS (GCS) | 15 | 13-14 | 10-12 | 6-9 | <6 |
| Renal (Creatinine/UOP) | <1.2 | 1.2-1.9 | 2.0-3.4 | 3.5-4.9 or UOP <500 | >5 or UOP <200 |
Septic shock = Sepsis + vasopressor requirement to maintain MAP ≥65 + lactate >2 mmol/L despite adequate volume resuscitation.
All elements should be initiated within 1 hour of sepsis recognition:
| Element | Target | SEP-1 Metric Window |
|---|---|---|
| Measure lactate | Initial level within 6 hours | Must be drawn within 6 hours of time zero |
| Obtain blood cultures before antibiotics | 2 sets (4 bottles) from 2 sites | Must be drawn before first antibiotic dose |
| Administer broad-spectrum antibiotics | Appropriate empiric coverage for suspected source | Within 3 hours (present on admission) or 1 hour (severe sepsis/shock) |
| Administer 30 mL/kg crystalloid | For hypotension (MAP <65) or lactate ≥4 | Start within 3 hours; complete within 6 hours |
| Apply vasopressors | If hypotension persists after fluid resuscitation | Document reassessment and vasopressor initiation |
| Remeasure lactate | If initial lactate >2 mmol/L | Within 6 hours of initial measurement |
| Source | Empiric Regimen | Key Considerations |
|---|---|---|
| Pneumonia (community) | Ceftriaxone + azithromycin OR respiratory fluoroquinolone | Consider MRSA coverage if risk factors |
| Pneumonia (hospital/ventilator) | Piperacillin-tazobactam or meropenem + vancomycin ± inhaled aminoglycoside | Anti-pseudomonal coverage required |
| Urinary tract | Ceftriaxone or fluoroquinolone | Piperacillin-tazobactam if complicated or resistant organisms |
| Intra-abdominal | Piperacillin-tazobactam or meropenem | Must cover anaerobes and gram-negatives |
| Skin/soft tissue | Vancomycin + piperacillin-tazobactam | Clindamycin for toxin suppression in necrotizing fasciitis |
| Unknown source | Vancomycin + piperacillin-tazobactam or meropenem | Broadest coverage; narrow when cultures return |
| Meningitis | Vancomycin + ceftriaxone + ampicillin (if >50 or immunocompromised) + dexamethasone | Dexamethasone before or with first antibiotic dose |
If MAP remains <65 mmHg after 30 mL/kg crystalloid (or clinician reassessment determines further fluid is unlikely to benefit):
| Agent | Starting Dose | Max Dose | Notes |
|---|---|---|---|
| Norepinephrine (first-line) | 0.1 mcg/kg/min | 1-2 mcg/kg/min | Alpha-1 >> beta-1; preferred vasoactive |
| Vasopressin (second-line adjunct) | 0.03-0.04 units/min | 0.04 units/min (fixed) | Add when norepinephrine 0.25-0.5 mcg/kg/min |
| Epinephrine (third-line) | 0.1 mcg/kg/min | Titrate to effect | For catecholamine-refractory shock with cardiac dysfunction |
| Phenylephrine | 0.5-2 mcg/kg/min | 5 mcg/kg/min | Pure alpha—limited role; consider if tachyarrhythmia limits others |
| Initial Lactate | Action | Repeat Timing |
|---|---|---|
| <2 mmol/L | Sepsis (not shock); standard monitoring | Not mandatory for SEP-1 but clinically prudent |
| 2-4 mmol/L | Indicates tissue hypoperfusion; guide resuscitation | Repeat within 2-4 hours |
| ≥4 mmol/L | Septic shock criterion; aggressive resuscitation | Repeat within 6 hours (SEP-1 requirement) |
Target: ≥10% lactate clearance per 2 hours OR normalization (<2 mmol/L). Failure to clear lactate despite adequate resuscitation suggests ongoing tissue hypoxia, need for source control, or mitochondrial dysfunction.
| # | Criterion | Pass/Fail |
|---|---|---|
| 1 | Time zero clearly identified and documented | |
| 2 | Sepsis-3 criteria met (infection + SOFA ≥2) and documented | |
| 3 | Initial lactate drawn within 6 hours of time zero | |
| 4 | Blood cultures drawn before antibiotic administration | |
| 5 | Antibiotics administered within 1 hour of sepsis recognition | |
| 6 | Antibiotic spectrum appropriate for suspected source | |
| 7 | 30 mL/kg crystalloid initiated within 3 hours for eligible patients | |
| 8 | Repeat lactate obtained within 6 hours if initial >2 mmol/L | |
| 9 | Vasopressor initiated for persistent hypotension post-fluids | |
| 10 | 6-hour physician reassessment documented | |
| 11 | Source control assessment documented with timeline | |
| 12 | Antibiotic de-escalation plan documented | |
| 13 | Weight used for fluid calculation documented | |
| 14 | All SEP-1 bundle element timestamps recorded | |
| 15 | Heart failure patients assessed for modified fluid approach |